Posted on 13 September 2011. Tags: Cardiovascular, Cirse, Clinical Trial, Congress, Dcth, Delcath Systems Inc, Europe, Metastatic, Munich Germany, Nasdaq, Phase 2, Radiological Society, tumor
Delcath Systems, Inc. (NASDAQ: DCTH) announced that updated results from the metastatic neuroendocrine tumor (mNET) cohort of the Company's recently completed Phase 2 clinical trial were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress held this week in Munich, Germany. James F...
Posted in Cancer News Today, Cancer Research